FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response	e: 0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Ballinger Kevin J.</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol Silk Road Medical Inc [ SILK ]									k all app	•			
(Last) (First) (Middle) 1213 INNSBRUCK DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 09/17/2024									Office below	er (give title v)		Other (s below)	specify
(Street) SUNNYVALE CA 94089					4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person  Form filed by More than One Reporting Person					
(City)		(State)	(Zip)																
		Tabl	e I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or l	Bene	ficiall	y Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day					Execution D		Date,	3. Transa Code ( 8)		on Disposed O		es Acquired (A Of (D) (Instr. 3,		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount (A) (C)		i) or					Price	(Instr. 4)
Common Stock 09/17/2					2024		D		23,666(1)		D	(2)(3)	0		D				
		Т	able II -								osed of, onvertib				Owne	d	,		
1. Title of Derivative Security (Instr. 3)	2. Conversi or Exerci Price of Derivative Security	e (Month/Day/Year	Execut ) if any	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exercion Da /Day/Y		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	,	(A)	(D)	Date Exercis	ablo	Expiration	Title	Amor or Numl of Share	ber					

## **Explanation of Responses:**

- 1. Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.
- 2. Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc. (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive \$27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.
- 3. Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.

/s/ Mhairi Jones, by power of attorney

\*\* Signature of Reporting Person

09/18/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.